BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015;63:1511-1522. [PMID: 26299621 DOI: 10.1016/j.jhep.2015.08.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Popping S, Cento V, García F, Ceccherini-silberstein F, Seguin-devaux C, Vijver DA, Boucher CA. The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. Journal of Virus Eradication 2018;4:179-81. [DOI: 10.1016/s2055-6640(20)30267-3] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
2 Tavares RCF, Feldner ACCA, Pinho JRR, Uehara SNO, Emori CT, Carvalho-Filho RJ, Silva ISS, Santana RAF, de Castro VFD, Castoli GTF, Cristovão CU, Ferraz MLCG. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2017;29:754-8. [PMID: 28234637 DOI: 10.1097/MEG.0000000000000866] [Reference Citation Analysis]
3 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
4 Hézode C, Fourati S, Chevaliez S, Scoazec G, Soulier A, Varaut A, François M, Ruiz I, Roudot-Thoraval F, Mallat A, Pawlotsky JM. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C. Clin Infect Dis 2017;64:1615-8. [PMID: 28369411 DOI: 10.1093/cid/cix214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
5 Mushtaq S, Mansoor A, Umar M, Khan A, Siddiqi S, Manzoor S. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan. J Med Virol 2020. [PMID: 32129507 DOI: 10.1002/jmv.25745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. Liver Int 2021;41:1802-14. [PMID: 33497016 DOI: 10.1111/liv.14797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Naguib GG, Michael TG, Elshazly Y, Wahdan MM, Mostafa A, Ahmed OA, Dabbous H, Aly HIS, Shaker MK, Elbaz HS, El-Serafy M, Doss W, Abd-Elsalam S, El-Sayed MH. The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. Virusdisease 2021;32:582-8. [PMID: 34631983 DOI: 10.1007/s13337-021-00712-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C. Deep sequencing in the management of hepatitis virus infections. Virus Res 2017;239:115-25. [PMID: 28040474 DOI: 10.1016/j.virusres.2016.12.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
9 Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Llerena S, Cabezas J, Iruzubieta P, Crespo J. Resistance to hepatitis C virus. Implications and therapeutic options. Gastroenterol Hepatol 2017;40:484-94. [PMID: 28647053 DOI: 10.1016/j.gastrohep.2017.04.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T, Suzuki R, Kato N, Watanabe M, Wakita T. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Sci Rep. 2016;6:34652. [PMID: 27703205 DOI: 10.1038/srep34652] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
12 Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015;7:5746-5766. [PMID: 26561827 DOI: 10.3390/v7112902] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
13 Nieto-Aponte L, Quer J, Ruiz-Ripa A, Tabernero D, Gonzalez C, Gregori J, Vila M, Asensio M, Garcia-Cehic D, Ruiz G, Chen Q, Ordeig L, Llorens M, Saez M, Esteban JI, Esteban R, Buti M, Pumarola T, Rodriguez-Frias F. Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. J Clin Microbiol 2017;55:504-9. [PMID: 27927921 DOI: 10.1128/JCM.01960-16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
15 Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group. Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res 2021;51:51-61. [PMID: 33021009 DOI: 10.1111/hepr.13576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Ghanem SE, Elsabaawy M, Shebl N, Abdelsameea E, Othman W, El-Bassal FI, Elgedawy GA, Elsabaawy DM, Helal ML. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert Rev Anti Infect Ther 2020;18:947-54. [PMID: 32419526 DOI: 10.1080/14787210.2020.1771180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Takeda H, Ueda Y, Inuzuka T, Yamashita Y, Osaki Y, Nasu A, Umeda M, Takemura R, Seno H, Sekine A, Marusawa H. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Sci Rep. 2017;7:45605. [PMID: 28361915 DOI: 10.1038/srep45605] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
18 Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52-62. [PMID: 28404015 DOI: 10.1016/s2468-1253(16)30080-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
19 Nakamura F, Takeda H, Ueda Y, Takai A, Takahashi K, Eso Y, Arasawa S, Iguchi E, Shimizu T, Mishima M, Kumagai K, Yamashita T, Uemoto S, Kato N, Marusawa H, Sekine A, Seno H. Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing. Sci Rep 2022;12:7083. [PMID: 35490163 DOI: 10.1038/s41598-022-11151-6] [Reference Citation Analysis]
20 Shawky H, El-Shenawy R, Helmy NM. Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients. Hum Antibodies 2021. [PMID: 34511496 DOI: 10.3233/HAB-211504] [Reference Citation Analysis]
21 Domínguez-domínguez L, Bisbal O, Matarranz M, Lagarde M, Pinar Ó, Hernando A, Lumbreras C, Rubio R, Pulido F. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection. Eur J Clin Microbiol Infect Dis 2019;38:725-34. [DOI: 10.1007/s10096-019-03488-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Li JR, Li WJ, Cheng JJ, Huang MH, Wu ZY, Jiang CC, Li H, Chen JH, Lv XQ, Dong B, Jiang JD, Peng ZG. A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System. Biomed Res Int 2017;2017:1236801. [PMID: 28904942 DOI: 10.1155/2017/1236801] [Reference Citation Analysis]
23 Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016;11:e0163884. [PMID: 27684567 DOI: 10.1371/journal.pone.0163884] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514-528. [PMID: 28105744 DOI: 10.1111/liv.13327] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
25 Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol 2020;11:550205. [PMID: 32982753 DOI: 10.3389/fphar.2020.550205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, Peña JM, Barreiro P. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother 2016;17:217-29. [PMID: 26595348 DOI: 10.1517/14656566.2016.1112790] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
27 Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017;67:585-602. [PMID: 28323126 DOI: 10.1016/j.jhep.2017.03.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 38] [Article Influence: 11.4] [Reference Citation Analysis]
28 Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
29 Abo-Amer YE, Badawi R, El-Abgeegy M, Elsergany HF, Mohamed AA, Mostafa SM, Alegaily HS, Soliman S, Elnawasany S, Abd-Elsalam S. Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure. Adv Virol 2020;2020:9075905. [PMID: 32774374 DOI: 10.1155/2020/9075905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Shah S, Chougule MB, Kotha AK, Kashikar R, Godugu C, Raghuvanshi RS, Singh SB, Srivastava S. Nanomedicine based approaches for combating viral infections. J Control Release 2021;338:80-104. [PMID: 34375690 DOI: 10.1016/j.jconrel.2021.08.011] [Reference Citation Analysis]
31 Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother 2017;18:1235-42. [PMID: 28644739 DOI: 10.1080/14656566.2017.1346609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
32 Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 2018;18:446. [PMID: 30176817 DOI: 10.1186/s12879-018-3356-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
33 Ledezma-morales M, Amariles P, Salazar-ospina A, Duque-zapata N, Gómez Cárdenas J, Vargas-peláez CM, Rossi FA. Effect of strategic purchasing of antiviral drugs and the clinical pathway for the treatment of Chronic Hepatitis C in Colombia (hepC-STRATEGY): study protocol for a quasi-experimental study. Journal of Pharmaceutical Health Services Research 2021;12:173-80. [DOI: 10.1093/jphsr/rmaa032] [Reference Citation Analysis]
34 Ran M, Huang J, Liang H, Jiang J, Liang B, Ning C, Zang N, Liao W, Liu H, Qin F, Yang Q, Ho W, Ye L, Chen H. Alcohol attenuates anti-HCV function of IFN-λ1 through up-regulation of PLASy expression in human hepatic cells. J Med Virol 2018;90:1112-20. [PMID: 29446489 DOI: 10.1002/jmv.25053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Jiménez-Pérez M, González-Grande R, España Contreras P, Pinazo Martínez I, de la Cruz Lombardo J, Olmedo Martín R. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World J Gastroenterol 2016; 22(29): 6573-6581 [PMID: 27547001 DOI: 10.3748/wjg.v22.i29.6573] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
36 Chen Q, Perales C, Soria ME, García-Cehic D, Gregori J, Rodríguez-Frías F, Buti M, Crespo J, Calleja JL, Tabernero D, Vila M, Lázaro F, Rando-Segura A, Nieto-Aponte L, Llorens-Revull M, Cortese MF, Fernandez-Alonso I, Castellote J, Niubó J, Imaz A, Xiol X, Castells L, Riveiro-Barciela M, Llaneras J, Navarro J, Vargas-Blasco V, Augustin S, Conde I, Rubín Á, Prieto M, Torras X, Margall N, Forns X, Mariño Z, Lens S, Bonacci M, Pérez-Del-Pulgar S, Londoño MC, García-Buey ML, Sanz-Cameno P, Morillas R, Martró E, Saludes V, Masnou-Ridaura H, Salmerón J, Quíles R, Carrión JA, Forné M, Rosinach M, Fernández I, García-Samaniego J, Madejón A, Castillo-Grau P, López-Núñez C, Ferri MJ, Durández R, Sáez-Royuela F, Diago M, Gimeno C, Medina R, Buenestado J, Bernet A, Turnes J, Trigo-Daporta M, Hernández-Guerra M, Delgado-Blanco M, Cañizares A, Arenas JI, Gomez-Alonso MJ, Rodríguez M, Deig E, Olivé G, Río OD, Cabezas J, Quiñones I, Roget M, Montoliu S, García-Costa J, Force L, Blanch S, Miralbés M, López-de-Goicoechea MJ, García-Flores A, Saumoy M, Casanovas T, Baliellas C, Gilabert P, Martin-Cardona A, Roca R, Barenys M, Villaverde J, Salord S, Camps B, Silvan di Yacovo M, Ocaña I, Sauleda S, Bes M, Carbonell J, Vargas-Accarino E, Ruzo SP, Guerrero-Murillo M, Von Massow G, Costafreda MI, López RM, González-Moreno L, Real Y, Acero-Fernández D, Viroles S, Pamplona X, Cairó M, Ocete MD, Macías-Sánchez JF, Estébanez A, Quer JC, Mena-de-Cea Á, Otero A, Castro-Iglesias Á, Suárez F, Vázquez Á, Vieito D, López-Calvo S, Vázquez-Rodríguez P, Martínez-Cerezo FJ, Rodríguez R, Macenlle R, Cachero A, Mereish G, Mora-Moruny C, Fábregas S, Sacristán B, Albillos A, Sánchez-Ruano JJ, Baluja-Pino R, Fernández-Fernández J, González-Portela C, García-Martin C, Sánchez-Antolín G, Andrade RJ, Simón MA, Pascasio JM, Romero-Gómez M, Antonio Del-Campo J, Domingo E, Esteban R, Esteban JI, Quer J. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res 2020;174:104694. [PMID: 31857134 DOI: 10.1016/j.antiviral.2019.104694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
37 Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
38 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Portari-Filho LH, Álvares-da-Silva MR, Gonzalez A, Ferreira AP, Villela-Nogueira CA, Mendes-Correa MC, Lima JM, Lopes EP, Brandão CE, Ivantes C, Lyra A, Lindenberg A, Ferraz ML. How are HCV-infected patients being identified in Brazil: a multicenter study. Braz J Infect Dis 2019;23:34-9. [PMID: 30849332 DOI: 10.1016/j.bjid.2019.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Bobardt M, Ramirez CM, Baum MM, Ure D, Foster R, Gallay PA. The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. PLoS One 2021;16:e0251934. [PMID: 34014993 DOI: 10.1371/journal.pone.0251934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol 2016;22:432-8. [PMID: 28081594 DOI: 10.3350/cmh.2016.0107] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
42 Chueca N, Rivadulla I, Lovatti R, Reina G, Blanco A, Fernandez-Caballero JA, Cardeñoso L, Rodriguez-Granjer J, Fernandez-Alonso M, Aguilera A, Alvarez M, Galán JC, García F. Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. PLoS One 2016;11:e0153754. [PMID: 27097040 DOI: 10.1371/journal.pone.0153754] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
43 Debnath P, Chandnani S, Rathi P, Nair S, Junare P, Udgirkar S, Singh A, Contractor Q. A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus. Clin Exp Hepatol 2020;6:253-62. [PMID: 33145432 DOI: 10.5114/ceh.2020.99525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Tavares RCF, de Castro Amaral Feldner AC, Pinho JRR, de Mello Malta F, Carvalho-Filho RJ, Santana RAF, de Castro VFD, Dastoli GTF, Lima JC, Ferraz MLCG. Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus. Infect Drug Resist 2018;11:1993-2000. [PMID: 30464541 DOI: 10.2147/IDR.S169512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Bourlière M, Pietri O. Hepatitis C virus therapy: No one will be left behind. Int J Antimicrob Agents 2019;53:755-60. [PMID: 30605721 DOI: 10.1016/j.ijantimicag.2018.12.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
46 Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd-Elsalam S. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018;11:441-445. [PMID: 29628768 DOI: 10.2147/idr.s160593] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
47 Walker A, Kaiser R, Bartenschlager R, Timm J. Genotypic resistance testing of HCV - is there a clinical need? GMS Infect Dis 2016;4:Doc05. [PMID: 30671319 DOI: 10.3205/id000023] [Reference Citation Analysis]
48 Arias A, Aguilera A, Soriano V, Benítez-Gutiérrez L, Lledó G, Navarro D, Treviño A, Otero E, Peña JM, Cuervas-Mons V, de Mendoza C. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther 2017;22:307-12. [PMID: 27341294 DOI: 10.3851/IMP3061] [Cited by in Crossref: 39] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
49 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 276] [Article Influence: 98.7] [Reference Citation Analysis]
50 Benítez-Gutiérrez L, Barreiro P, Labarga P, de Mendoza C, Fernandez-Montero JV, Arias A, Peña JM, Soriano V. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother 2016;17:1215-23. [PMID: 27149603 DOI: 10.1080/14656566.2016.1182156] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
51 Castellote J, Gea F, Morano LE, Morillas RM, Pineda JA, Vergara M, Buti M. Factors influencing hepatitis C cure in the era of direct-acting antivirals. Gastroenterol Hepatol 2019;42 Suppl 1:1-7. [PMID: 32560767 DOI: 10.1016/S0210-5705(20)30181-3] [Reference Citation Analysis]
52 Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016;11:e0163884. [PMID: 27684567 DOI: 10.1371/journal.pone.0163884pone-d-16-27137] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 El Kassas M, Alboraie M, El Badry M, Youssef N, Omar H, El Sheemy RY, Al Balakosy A, Ashraf Ahmed Mohamed O, Gamal Naguib Meleak G, Dabbous H, Hassan Ahmed Fouad M, Wifi MN, Zaky S, Tahoon M, El Tahan A, El-Raey F, Ezzat S, Doss W. Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study. Int J Infect Dis 2020;96:367-70. [PMID: 32325275 DOI: 10.1016/j.ijid.2020.04.022] [Reference Citation Analysis]
54 Itakura J, Kurosaki M, Hasebe C, Osaki Y, Joko K, Yagisawa H, Sakita S, Okushin H, Satou T, Hisai H, Abe T, Tsuji K, Tamada T, Kobashi H, Mitsuda A, Ide Y, Ogawa C, Tsuruta S, Takaguchi K, Murakawa M, Asahina Y, Enomoto N, Izumi N. Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS One 2016;11:e0165339. [PMID: 27776192 DOI: 10.1371/journal.pone.0165339] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
55 Soriano V, Benítez-Gutiérrez L, Arias A, Carrasco I, Barreiro P, Peña JM, de Mendoza C. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol 2017;13:1015-22. [PMID: 28753040 DOI: 10.1080/17425255.2017.1359254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
56 Sung PS, Hong SH, Chung JH, Kim S, Park SH, Kim HM, Yoon SK, Shin EC. IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection. Sci Rep 2017;7:3821. [PMID: 28630501 DOI: 10.1038/s41598-017-04186-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]